Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Frequently asked questions
What sector does Clearside Biomedical Inc. (CLM) operate in?
Clearside Biomedical Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Clearside Biomedical Inc. (CLM) current stock price?
As of the latest data, Clearside Biomedical Inc. stock price is €4.35, with a previous close of €4.35.
What is Clearside Biomedical Inc. (CLM) current market capitalization?
Clearside Biomedical Inc. market cap is approximately 22.77 million.
What is Clearside Biomedical Inc. (CLM) Earnings Per Share (EPS)?
The trailing EPS is -€4.59.
Does Clearside Biomedical Inc. (CLM) pay dividends?
No. Clearside Biomedical Inc. does not pay a dividend.
What is Clearside Biomedical Inc. (CLM) beta (volatility) score?
Clearside Biomedical Inc. has a beta of 2.112, indicating very high volatility compared to the market.